Prostate Cancer

Prostate cancer is a malignant neoplasm arising from the glandular cells of the prostate gland. It is typically a slow-growing tumor, though aggressive variants exist. It primarily affects the peripheral zone of the prostate and is hormone-dependent, specifically requiring androgens for growth.

Etiology involves a multifactorial interplay between somatic mutations, germline predispositions, and chronic inflammation. Hormonal signaling via androgen receptors (AR) is the primary driver of tumorigenesis.

Prostate cancer begins with prostatic intraepithelial neoplasia (PIN), progressing to invasive adenocarcinoma. The tumor creates a disorganized glandular architecture, characterized by the loss of the basal cell layer. Metastasis typically occurs via lymphatics to pelvic nodes or hematogenously to the axial skeleton.

It is the most common non-skin cancer in men. Prevalence increases significantly after age

1. Incidence varies by ethnicity, with higher rates observed in African American populations.

Age (≥50), African ancestry, family history (BRCA1/2 mutations), high-fat diet, obesity, and sedentary lifestyle.

A. Early Symptoms
Asymptomatic. B. Common Symptoms
Difficulty initiating urination, weak stream, nocturia, urinary frequency. C. Advanced Symptoms
Hematuria, hematospermia, erectile dysfunction, pelvic pain. D. Emergency Symptoms
Spinal cord compression (back pain with motor/sensory deficits), acute urinary retention, pathological fractures.

Digital Rectal Exam (DRE) may reveal firm, irregular, or nodular induration of the prostate gland.

A. Clinical Assessment: DRE.
B. Laboratory Testing: Prostate-Specific Antigen (PSA) levels.
C. Imaging Studies: Multiparametric MRI (mpMRI).
D. Functional Tests: Not routine.
E. Biopsy Findings: Gleason Score/Grade Group.
F. Genetic Testing: BRCA, HOXB13 for hereditary risk.
G. Differential Diagnosis: Benign Prostatic Hyperplasia (BPH), Prostatitis.

Prostate-Specific Antigen (PSA)
Type: Blood Test
Purpose: Screening and monitoring.
Expected Findings: >4.0 ng/mL is often abnormal.
Interpretation: Elevated levels suggest prostate pathology; requires correlation with biopsy.

mpMRI: Identifies suspicious lesions (PI-RADS scoring) to guide biopsy.
Bone Scan: Detects osteoblastic metastatic spread.

BPH (symmetrical enlargement), Prostatitis (tenderness, fever), Bladder cancer.

Urinary incontinence, erectile dysfunction, bone fractures, anemia.

A. Lifestyle Modifications: Mediterranean diet, exercise.
B. Preventive Measures: Screening from age 50 (45 if high risk).
C. Medical Treatment
Androgen Deprivation Therapy (ADT): Leuprolide, Degarelix.
D. Surgical Treatment: Radical Prostatectomy.
E. Interventional Procedures: Radiation therapy, Cryotherapy.
F. Rehabilitation: Pelvic floor physical therapy.
G. Emergency Management: Surgery for cord compression.

Generally favorable for localized disease (5-year survival >99%). Metastatic disease prognosis is variable depending on treatment response.

Early screening using PSA and DRE; dietary management.

The following homeopathic remedies have been historically indicated for symptoms associated with Prostate Cancer. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

📊 Men's Prostate & Testosterone Analyzer

Evaluates PSA levels for prostate cancer screening, testosterone deficiency (hypogonadism), BPH symptom severity (IPSS score), and male hormonal health profile.